Back

Wilson Therapeutics AB (publ) Interim Report January 1 – March 31, 2017

May 17, 2017

Preparations for Phase 3 progressing according to plan

January 1 – March 31, 2017

  • Net sales amounted to SEK 0.0 M (0.0)
  • Loss for the period was SEK 31.4 M (loss: 22.3)
  • Loss per share, before and after dilution, totaled SEK 1.22 (loss: 17.62)
  • At March 31, cash and cash equivalents amounted to SEK 339.3 M (53.0)

Significant events during the period

Extraordinary general meeting was held in January 2017 and resolved to implement a long term incentive program

Significant events after the end of the period

  • Data from the successfully completed Phase 2 trial were presented at major scientific conferences

”During the first part of the year we have been engaged in analyzing and presenting the data from our Phase 2 trial that was successfully completed towards the end of last year. We have also met with the US FDA and continue to work collaboratively towards finalizing the Phase 3 trial design. The discussions are still ongoing but we are now in broad agreement on the trial design and reiterate our expectation to initiate the Phase 3 trial during the second half of 2017.”

Jonas Hansson, CEO of Wilson Therapeutics.

Invitation to telephone conference
All interested parties are invited to participate in a web-cast telephone conference regarding the report today May 17 at 10:00 CET. The live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q1-2017. Questions can be asked in writing via the webcast or verbally via the conference call.

To participate in the conference call, please call one of the following numbers:

  • SE: +46 8 566 426 62
  • UK: +44 203 008 9803
  • US: +1 855 831 5947

The presentation material will also be published before the conference starts on Wilson Therapeutics’ website www.wilsontherapeutics.com under Media & Investors/ Presentations. The webcast, and later the recorded version of the webcast and the conference call, will also be accessible via Wilson Therapeutics’ website.

About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.

Visit www.wilsontherapeutics.com for more information.

For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Email: es.xt1495728157w@nos1495728157snah.1495728157sanoj1495728157

Wilson Therapeutics AB (publ)
Corp. Reg. No. 556893-0357
Kungsgatan 3
SE-111 43 Stockholm

The information in the interim report is information that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.00 CET on May 17, 2017.